Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,739 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,739 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired…(DREAMM 13) | Phase 1 | withdrawn | May 21, 2020 | GlaxoSmithKline | Sponsor Decision | Sponsor / business decision |
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of… | Phase 1 | terminated | Oct 19, 2021 | Henan Cancer Hospital | The clinical development of parsaclisib was stopped by it's manufacturer. | Drug supply |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | Phase 1 | terminated | Mar 12, 2024 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT01316523 | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's… | Phase 2 | terminated | Mar 16, 2011 | University of California, Davis | Sponsor choice | Other (stated, no rule matched) |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Phase 2 | terminated | Apr 13, 2018 | University of Washington | Closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell… | Phase 1 | terminated | Oct 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | Incyte Corporation | This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Safety / toxicity |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic…(LIMBER) | Phase 1 / Phase 2 | terminated | Oct 9, 2020 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in… | Phase 2 | terminated | Jul 18, 2018 | University of California, San Diego | The trial met its primary endpoint. | Other (stated, no rule matched) |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 | terminated | Dec 27, 2021 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | Phase 1 | withdrawn | Dec 11, 2014 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn by PI | Other (stated, no rule matched) |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Phase 1 | terminated | Jan 27, 2020 | Novartis Pharmaceuticals | Business, strategic, and development considerations and not due to any safety concerns | Safety / toxicity |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT03287908 | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or… | Phase 1 | terminated | Sep 19, 2017 | Amgen | business decision, not safety reasons. | Safety / toxicity |
| NCT04405167 | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Phase 1 | terminated | May 28, 2020 | University of Pennsylvania | Slow accrual at the time when sufficient participants were already enrolled to answer the… | Enrollment / accrual |
| NCT01258933 | Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy | Phase 2 | terminated | Dec 13, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT04300335 | The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma | N/A | suspended | Mar 9, 2020 | Medical University of Vienna | The study was not started because the necessary resources could not yet be secured after COVID-19,… | COVID-19 / pandemic |
| NCT04111809 | Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With…(AMBROBiMM) | — | terminated | Oct 1, 2019 | Assistance Publique - Hôpitaux de Paris | Inability to conduct the study | Other (stated, no rule matched) |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Aug 30, 2023 | Genmab | Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio. | Sponsor / business decision |
| NCT04473937 | Radiation Post-CAR T in Refractory Lymphoma | N/A | terminated | Jul 16, 2020 | Massachusetts General Hospital | Futility | Efficacy / futility |
| NCT03769181 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Sanofi | Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the… | Safety / toxicity |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | Phase 1 | withdrawn | May 4, 2020 | National Cancer Institute (NCI) | Other - Clinical development of the agent has been discontinued | Other (stated, no rule matched) |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | Phase 2 | terminated | Feb 3, 2022 | Pentixapharm AG | The study was early terminated due to low patient recruitment in already activated sites and… | Enrollment / accrual |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With… | Phase 1 / Phase 2 | terminated | Nov 23, 2022 | Pfizer | The trial terminated due to the inability to recruit the planned number of subjects. The decision… | Safety / toxicity |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom… | Phase 1 | terminated | Sep 9, 2010 | M.D. Anderson Cancer Center | \<75% participant accrual | Enrollment / accrual |
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell… | Phase 1 | terminated | Aug 5, 2022 | Antengene (Hangzhou) Biologics Co., Ltd. | The sponsor has decided to adjust the development strategy of the investigational drug in this… | Sponsor / business decision |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Phase 2 | terminated | Aug 24, 2018 | Seagen Inc. | The study was prematurely discontinued as the sponsor believes the data collected is enough to show… | Safety / toxicity |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in… | Phase 2 | terminated | Dec 18, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | loss of funding | Funding |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | Phase 2 | terminated | Jun 1, 2023 | Affimed GmbH | Due to sponsor decision | Sponsor / business decision |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 1 | terminated | Jan 10, 2017 | Mayo Clinic | Drug company decided to not fund the phase 2 portion | Funding |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Phase 1 | terminated | Sep 14, 2016 | Novartis Pharmaceuticals | The decision of early termination was made due to business reasons, and was not based on any safety… | Safety / toxicity |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT04433182 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large… | Phase 2 | terminated | Jun 16, 2020 | Fondazione Italiana Linfomi - ETS | low enrollment rate | Enrollment / accrual |
| NCT05655546 | ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised… | N/A | terminated | Dec 19, 2022 | Scripps Translational Science Institute | On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used. | Other (stated, no rule matched) |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | withdrawn | Aug 22, 2023 | Juventas Cell Therapy Ltd. | Sponsor changed product development plan | Other (stated, no rule matched) |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Sep 19, 2024 | University of Washington | Study terminated due to end of funding. | Funding |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+…(NAVAL-1) | Phase 2 | terminated | Aug 18, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03249792 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination… | Phase 1 | terminated | Aug 15, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04493411 | Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using… | N/A | terminated | Jul 30, 2020 | University of Texas Southwestern Medical Center | Funding expired before enrollment goal could be reached. | Enrollment / accrual |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or… | Phase 2 | terminated | Jan 17, 2018 | University of Washington | Study terminated to end of funding. | Funding |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | — | terminated | Oct 14, 2019 | AstraZeneca | Study stopped due to lack of recruitment. | Enrollment / accrual |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment…(ALEXANDER) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | After reviewing the data and taking into consideration the available treatment landscape in r/r… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 4, 2025source: clinicaltrials